AI Summary
✦ ClarthaArtemis Medicare Services is a hospital operator managing multispecialty facilities in India and internationally. Inpatient and outpatient medical services drive core revenue, supported by surgical interventions and international-patient programs. Billing, insurance, diagnostics, and home-care services add ancillary revenue streams. Q1 FY27 revenue rose 12.7%, while profit increased 48.3%, indicating operating leverage and improved earnings conversion. The stable margin trend offers limited evidence of structural expansion, while ROE is unavailable for assessing capital efficiency. Debt-to-equity of 27.8 implies extreme leverage, which can materially inflate reported ROE and increase financial risk. At 138.1 times earnings, the shares appear overvalued relative to hospital-sector growth expectations. The key open question is whether recent profit acceleration can persist without worsening leverage or compressing margins.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 5 analysts
Fundamentals
Fundamentals institutional score is 87 using growth durability 86.7.
Valuation
Valuation institutional score is 54 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 80 using mean target upside 9.7%; dispersion penalty 5.2; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 22 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and analyst consensus provide support, while valuation and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 29.7% above historical median. Valuation is declining — currently in the strongly overvalued zone (z-score: +1.61). Confidence: 78%.
Live forward EPS implies next-12-month EPS of ₹12.43. Applying the stock's normalized valuation corridor produces a fair range of ₹993.41 to ₹1,479.42, with base value near ₹1,321.81 (+318.4% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹12.43
Forward P/E
25.4x
Base Fair Value
₹1,321.81
Fair Range
₹993.41 - ₹1,479.42
Upside To Base
+318.4%
Estimate Source
Live forward EPS
Growth Estimate
+46.7%
5Y Average
74.21
Current
137.97
Overvalued
119.02
Undervalued
79.92
5Y Average
14.27
Current
26.53
Overvalued
21.49
Undervalued
5.82
5Y Average
—
Current
5.35
Overvalued
6.15
Undervalued
4.55
Peers & Comparison
Sector: Industrials · Theme: Business Support Services
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
KFIN TECHNOLOGIES LIMITED KFINTECHBusiness Support Services | +30.1% | 24.4% | 47.6x Premium | +23% vs avg | -14.5% |
INDEGENE LIMITED INDGNBusiness Support Services | +39.7% | 10.5% | 34.9x Fair | -10% vs avg | -3.5% |
RITES LIMITED RITESBusiness Support Services | +8.7% | 17.0% | 26.6x Undervalued | -31% vs avg | -6.5% |
SIS LIMITED SISBusiness Support Services | +29.7% | 0.9% | 45.2x Premium | +17% vs avg | +19.5% |
ARTEMIS MED SERVICE LTD trades at a premium (138.1x vs peer avg 38.6x), implying higher growth or quality expectations from the Business Support Services cohort. Peers include KFIN TECHNOLOGIES LIMITED, INDEGENE LIMITED, RITES LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹282 CrJun 2026Latest net profit
₹31 CrJun 2026Latest EPS
₹1.96Jun 2026Net margin
20.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 201 | 217 | 210 | 217 | 217 | 235 | 227 | 235 | 250 | 270 | 267 | 274 | 282 |
| Expenses + | 174 | 184 | 179 | 181 | 181 | 193 | 190 | 199 | 209 | 220 | 223 | 224 | 227 |
| Operating Profit | 27 | 33 | 32 | 36 | 36 | 42 | 37 | 36 | 41 | 50 | 44 | 50 | 55 |
| OPM % | 14% | 15% | 15% | 17% | 16% | 18% | 16% | 15% | 16% | 19% | 16% | 18% | 20% |
| Other Income + | 1 | 2 | 2 | 2 | 4 | 8 | 9 | 12 | 7 | 8 | 4 | 8 | 5 |
| Interest | 6 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 6 | 6 |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 |
| Profit before tax | 13 | 19 | 16 | 19 | 22 | 31 | 27 | 29 | 30 | 40 | 30 | 39 | 42 |
| Tax % | 26% | 27% | 29% | 28% | 24% | 27% | 23% | 20% | 29% | 25% | 24% | 25% | 26% |
| Net Profit + | 10 | 14 | 12 | 14 | 17 | 23 | 21 | 23 | 21 | 30 | 23 | 30 | 31 |
| EPS in Rs | 0.73 | 1.01 | 0.85 | 1.02 | 1.24 | 1.64 | 1.51 | 1.69 | 1.54 | 2.16 | 1.42 | 1.87 | 1.96 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Monitoring Agency Report